PCSA · Processa Pharmaceuticals, Inc. · Financials
$1.99
-0.17 (-7.87%)
At close · Sep 9
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“Following our acquisition of Vidya and closing of the related $200 million gross private placement (from which we received net proceeds of $183.3 million) on July 30, 2026, we believe our cash and cash equivalents will be sufficient to satisfy our cash requirements over the next 12 months and beyond. This represents a material change from what we reported in our 2025 Form 10-K that disclosed substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.56M
Shares
2.79M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
FY2022
Net Income
-$13.56M
-14.5%
FY2025
Gross Margin
100%
+111pp
FY2016
Operating Margin
-38430.4%
FY2016
Diluted EPS
-$10.36
+89.3%
FY2025
Operating Cash Flow
-$11.39M
-1.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | — | — | — | $0 | $0 | — | — | — | — | $5000 | $113.43K | $107.24K | $312.48K | $192.15K | |
| — | — | — | — | — | — | — | — | — | — | — | $125.88K | $66.83K | $188K | $133.26K | |
| — | — | — | — | — | — | — | — | — | — | $5000 | -$12.45K | $40.41K | $124.48K | $58.89K | |
| — | — | — | — | — | — | — | — | — | — | 100% | -10.98% | 37.68% | 39.84% | 30.65% | |
| $6.23M | $7.81M | $7.27M | $5.8M | $11.49M | $6.88M | $3.17M | $2.32M | $3.09M | $964.16K | $1.54M | $29.25K | $178.09K | $267.06K | $448.03K | |
| $6.62M | $6.18M | $4.78M | $5.66M | $8.76M | $4.69M | $3.26M | $1.61M | $1.44M | — | — | — | — | — | — | |
| $1.37M | — | — | — | — | — | — | — | $1.44M | $838.27K | $69.97K | $945.46K | $2.02M | $2.82M | $1.88M | |
| — | — | — | — | $788.5K | $790.49K | $795.33K | $795.33K | $621.65K | — | — | $178.57K | $357.14K | $357.14K | — | |
| — | — | — | — | — | — | — | — | — | $1.8M | $1.92M | $2.68M | $3.41M | $3.09M | $2.33M | |
| -$12.86M | -$13.99M | -$12.05M | -$11.46M | -$27.53M | -$12.13M | -$15.14M | -$3.94M | -$4.52M | -$1.8M | -$1.92M | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | -38430.4% | — | — | — | — | |
| — | — | — | — | — | $362 | $281.12K | $36.66K | $161.21K | $59.06K | $245.38K | $235.64K | $315.3K | -$109.73K | -$170.72K | |
| — | $109.49K | $201.09K | $335.54K | $101.2K | $11.63K | $3174 | $11.55K | $18.3K | $5181 | $4454 | $4651 | $155 | $2394 | $3131 | |
| — | -$13.56M | -$11.85M | -$11.12M | -$27.42M | -$11.96M | -$15.41M | -$3.96M | -$4.67M | -$1.86M | -$337.18K | -$2.98M | -$3.69M | -$3.07M | -$2.44M | |
| — | — | — | — | — | -$530.61K | -$1M | -$602.72K | -$902.8K | $258.58K | — | -$100 | -$100 | -$50 | -$181 | |
| -$13.44M | -$13.56M | -$11.85M | -$11.12M | -$27.42M | -$11.43M | -$14.41M | -$3.36M | -$3.77M | -$1.86M | -$1.92M | -$3.35M | -$4.53M | -$3.07M | -$2.44M | |
| — | — | — | — | — | — | — | — | — | — | -38341.32% | -2957.22% | -4220.71% | -982.05% | -1270.15% | |
| -$13.44M | -$13.56M | -$11.85M | -$11.12M | -$27.42M | -$11.43M | -$19.04M | -$3.86M | -$3.77M | — | -$379.04K | -$3.4M | -$6.03M | -$3.09M | -$2.77M | |
| USD/shares | $1.00 | -$10.36 | -$96.78 | -$212.00 | -$851.25 | -$375.00 | — | — | — | -$30.00 | -$35.00 | — | — | — | — |
| USD/shares | $1.00 | -$10.36 | -$96.78 | -$212.00 | -$851.25 | — | — | — | — | -$30.00 | -$35.00 | — | — | — | — |
| shares | — | 1.31M | 122.44K | 52.46K | 32.22K | 30.64K | 15K | 11.05K | 10.66K | 65.19K | 58.64K | 22.03K | 17.72K | 10.07K | 3686.066 |
| shares | — | 1.31M | 122.44K | 52.46K | 32.22K | 30.64K | 15K | 11.05K | 10.66K | 65.19K | 58.64K | 22.03K | 17.72K | 10.07K | 3686.066 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2015: $88.53K in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.19×
EV/EBIT
—
P/E (TTM)
—
Peer median 0.24×
Peer medians compare against the 166 similar-size Biotechnology companies (of 537 listed).
Key facts
CIK
1533743
CUSIP
74275C403
13F (30d)
12 filings
12 filers
Visit website
Investor relations